SEC 13F Intelligence

Managers / Q4 2021 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$414M
Q4 2021
Positions
68
Filings on Record
24
2019–present window
Filed
Feb 14, 2022
original filing

Summary

Endurant Capital Management LP reported $414M in U.S.-listed holdings across 68 positions for Q4 2021.

Its largest position, Invacare, represents 12.3% of the portfolio.

Compared with Q3 2021, the fund opened 32 new positions and exited 18.

Portfolio Metrics

Turnover
+40.7%
vs prior filed quarter
Top-10 Concentration
+47.5%
share of reported value
Largest Position
+12.3%
Invacare
New / Exited
32 / 18
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 54.6%US DOMESTIC: 12.3%ETP: 12.1%ADR: 10.5%Other: 8.2%Other: 2.3%
  • Common Stock · 54.6% · $226M
  • US DOMESTIC · 12.3% · $51M
  • ETP · 12.1% · $50M
  • ADR · 10.5% · $44M
  • Other · 8.2% · $34M
  • Other · 2.3% · $10M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
AZNNASTRAZENECA PLCNEW+324.7K324.7K+$19M$19M
SPDR SER TRNEW+163.2K163.2K+$18M$18M
CHARLES RIV LABS INTL INCNEW+18.6K18.6K+$7M$7M
CNCCENTENE CORP DELNEW+70.8K70.8K+$6M$6M
ORTHO CLINICAL DIAGNOSTICS HNEW+245.5K245.5K+$5M$5M
HAEHAEMONETICS CORP MASSNEW+73.9K73.9K+$4M$4M
SRPTSAREPTA THERAPEUTICS INCNEW+33.2K33.2K+$3M$3M
KINIKSA PHARMACEUTICALS LTDNEW+244.1K244.1K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2021

46 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1INVACARE CORPNOTE 5.000%11/114.63%$61M66.82M
2SNYSANOFIhistory →SPONSORED ADR5.13%$21M424.5K
3LABORATORY CORP AMER HLDGSCOM NEW4.96%$21M65.4K
4AZNNASTRAZENECA PLChistory →SPONSORED ADR4.57%$19M324.7K
5SIBNSI-BONE INChistory →COM4.11%$17M767.1K
6HUMHUMANA INChistory →COM3.80%$16M34.0K
7ABGAMERISOURCEBERGEN CORPhistory →COM3.69%$15M115.0K
8HO1HOLOGIC INChistory →COM3.35%$14M181.1K
9THCTENET HEALTHCARE CORPhistory →COM NEW2.90%$12M146.9K
10BUWABIO RAD LABS INChistory →CL A2.65%$11M14.5K
11XRAYDENTSPLY SIRONA INChistory →COM2.32%$10M172.4K
12BDXBECTON DICKINSON & COhistory →COM2.09%$9M34.5K
13CICIGNA CORP NEWhistory →COM2.03%$8M36.6K
148INSYNEOS HEALTH INChistory →CL A1.87%$8M75.3K
15JNJJOHNSON & JOHNSONhistory →COM1.77%$7M42.8K
16CHARLES RIV LABS INTL INCCOM1.69%$7M18.6K
17SELECTA BIOSCIENCES INCCOM1.67%$7M2.12M
18ELUTAZIYO BIOLOGICS INChistory →COM CL A1.64%$7M1.08M
19PKNPERKINELMER INChistory →COM1.43%$6M29.5K
20CNCCENTENE CORP DELhistory →COM1.41%$6M70.8K
21SPDR SER TRS&P BIOTECH1.32%$5M48.9K
22ORTHO CLINICAL DIAGNOSTICS HORD SHS1.27%$5M245.5K
23RCMEURR1 RCM INChistory →COM1.26%$5M205.4K
24OCULOCULAR THERAPEUTIX INChistory →COM1.21%$5M717.1K
25AVTRAVANTOR INChistory →COM1.09%$5M107.0K
26HAEHAEMONETICS CORP MASSCOM0.95%$4M73.9K
27VCYTVERACYTE INCCOM0.87%$4M87.3K
28ADAPYADAPTIMMUNE THERAPEUTICS PLCSPONDS ADR0.81%$3M897.6K
29SRPTSAREPTA THERAPEUTICS INCCOM0.72%$3M33.2K
30KINIKSA PHARMACEUTICALS LTDCOM CL A0.69%$3M244.1K
31ZGNXEURZOGENIX INCCOM NEW0.63%$3M160.6K
32IM8NINSMED INCCOM PAR $.010.59%$2M89.2K
33AHCOADAPTHEALTH CORPCOMMON STOCK0.58%$2M97.9K
34GDRXGOODRX HLDGS INCCOM CL A0.54%$2M68.6K
35FATEFATE THERAPEUTICS INCCOM0.53%$2M37.3K
36AXSMAXSOME THERAPEUTICS INCCOM0.51%$2M55.6K
37RYTMRHYTHM PHARMACEUTICALS INCCOM0.48%$2M197.5K
38ICUIICU MED INCCOM0.44%$2M7.8K
39VTLUSDIMMUNIC INCCOM0.43%$2M184.5K
40PRAXIS PRECISION MEDICINES ICOM0.43%$2M89.6K
41PODDINSULET CORPCOM0.41%$2M6.4K
42ATRCATRICURE INCCOM0.41%$2M24.3K
43SUTRO BIOPHARMA INCCOM0.40%$2M111.8K
44AUPHAURINIA PHARMACEUTICALS INCCOM0.37%$2M66.9K
45BDQMALBIREO PHARMA INCCOM0.37%$2M65.6K
46AXD2HERON THERAPEUTICS INCCOM0.36%$2M165.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.